ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15 million. The increase follows the announcement that ANTENGENE has entered into an agreement with UCB, granting the latter exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, consisting of a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to $1.1 billion in future milestone payments and tiered royalties based on net sales.